Paclitaxel Therapy Monitoring and Management

Introduction to Paclitaxel Therapy

The National Comprehensive Cancer Network recommends monitoring patients receiving paclitaxel therapy for neutropenia, peripheral neuropathy, hypersensitivity reactions, and myalgia/arthralgia, as these are the most common and potentially serious side effects that can impact morbidity, mortality, and quality of life 1

When combined with platinum agents, such as carboplatin, there is an increased risk of myelosuppression, and monitoring for cumulative neurotoxicity is recommended by the National Comprehensive Cancer Network 1
The American Society of Clinical Oncology suggests considering hydration protocols when combining paclitaxel with cisplatin to minimize the risk of nephrotoxicity 3

Peripheral neuropathy is a dose-dependent and cumulative effect of paclitaxel therapy, occurring in 46-79% of patients, with severe symptoms in 2-10%, according to the National Comprehensive Cancer Network 1
The National Comprehensive Cancer Network recommends regular evaluation for peripheral neuropathy symptoms and considering dose reduction if grade 2-3 neuropathy develops 2

The American College of Clinical Pharmacy recommends administering premedication regimens, including corticosteroids, diphenhydramine, and H₂-antagonists, before each cycle to prevent hypersensitivity reactions 1
The National Comprehensive Cancer Network suggests monitoring vital signs during infusion, especially during the first 30-60 minutes, and having emergency medications and equipment readily available 2

The Multinational Association of Supportive Care in Cancer recommends antiemetics for nausea/vomiting, pain management for myalgia/arthralgia, and oral care protocols for mucositis 1
The American Society of Clinical Oncology suggests considering G-CSF support if severe neutropenia occurs and delaying treatment if neutrophils <1,500 cells/mm³ or platelets <100,000 cells/mm³ 2

The National Comprehensive Cancer Network recommends closer monitoring for toxicities, considering starting at lower doses, and being aware of the higher risk of neurotoxicity and myelosuppression in certain patient populations 1
The American College of Clinical Pharmacy suggests reviewing all medications for potential interactions with paclitaxel and monitoring closely during infusion, especially in the first 15-30 minutes, for delayed recognition of hypersensitivity reactions 2